Carisma Therapeutics Announces Changes to its Board of Directors [Yahoo! Finance]
Carisma Therapeutics, Inc. (CARM)
Company Research
Source: Yahoo! Finance
July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden , M.D., to the Company's Board of Directors, effective June 30, 2024 . Additionally, Regina Hodits and Björn Odlander have informed the Board of their intention to step down as members effective June 30, 2024 , due to other professional commitments. "We are pleased to welcome David and Marella to the Carisma Board of Directors. Their vast experience in the life sciences sector will be instrumental in advancing our cell therapy platform focused on engineered macrophages," said Sanford Zweifach , Chair of the Carisma Board of Directors. "We would also like to thank Regina and Björn for their invaluable contributions, guidance, and leadership throughout their tenure. We wish them the utmost success in their fut
Show less
Read more
Impact Snapshot
Event Time:
CARM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CARM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CARM alerts
High impacting Carisma Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CARM
News
- Carisma Therapeutics Announces Changes to its Board of DirectorsPR Newswire
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna [Yahoo! Finance]Yahoo! Finance
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaPR Newswire
- Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Carisma Therapeutics' solid tumour therapy obtains FDA Fast Track status [Yahoo! Finance]Yahoo! Finance
CARM
Earnings
- 5/9/24 - Miss
CARM
Sec Filings
- 7/2/24 - Form 8-K
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- CARM's page on the SEC website